• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

MGMT 未甲基化以及高水平的 CD47 和 TIGIT 表明成人弥漫性神经胶质瘤预后不良。

MGMT unmethylation and high levels of CD47 and TIGIT indicate a poor prognosis in adult diffuse gliomas.

机构信息

NHC Key Laboratory of Prevention and Treatment of Central Asia High Incidence Diseases, The First Affiliated Hospital/Shihezi University School of Medicine, Shihezi, China.

Department of Pathology, First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.

出版信息

Front Immunol. 2024 Feb 9;15:1323307. doi: 10.3389/fimmu.2024.1323307. eCollection 2024.

DOI:10.3389/fimmu.2024.1323307
PMID:38404571
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10884119/
Abstract

INTRODUCTION

In 2021, the World Health Organization published a new classification system for central nervous system tumors. This study reclassified the adult diffuse glioma (ADG) into astrocytoma, oligodendroglioma, and glioblastoma (GBM) according to the new tumor classification.

METHODS

The association of TERT promoter (pTERT) mutation, MGMT methylation, and CD47/TIGIT expression with patient prognosis was investigated.

RESULTS

Immunohistochemical analysis showed that the expression levels of CD47 and TIGIT in tumor tissues were significantly higher than those in normal brain tissues. CD47 levels were higher in GBM and grade 4 astrocytoma tissues. TIGIT expression was also higher in patients with GBM. The high expressions of CD47, TIGIT, and CD47/TIGIT were positively correlated with unmethylation but not p mutation. Moreover, unmethylation was associated with poor overall survival in astrocytoma. High CD47, TIGIT, and CD47/TIGIT levels were associated with significantly reduced survival in ADG and GBM. GBM, unmethylation, and high CD47 expression were independent prognostic factors for overall survival in ADG.

DISCUSSION

Collectively, these results showed that the unmethylation and high levels of CD47 and TIGIT are associated with a poor prognosis in ADG. Patients with high CD47 and TIGIT expression may benefit from anti-CD47 and TIGIT immunotherapy.

摘要

简介

2021 年，世界卫生组织发布了新的中枢神经系统肿瘤分类系统。本研究根据新的肿瘤分类将成人弥漫性神经胶质瘤（ADG）重新分类为星形细胞瘤、少突胶质细胞瘤和胶质母细胞瘤（GBM）。

方法

研究了 TERT 启动子（pTERT）突变、MGMT 甲基化和 CD47/TIGIT 表达与患者预后的关系。

结果

免疫组化分析显示，肿瘤组织中 CD47 和 TIGIT 的表达水平明显高于正常脑组织。GBM 和 4 级星形细胞瘤组织中 CD47 水平较高。GBM 患者 TIGIT 表达也较高。CD47、TIGIT 和 CD47/TIGIT 的高表达与非甲基化但与 p 突变无关。此外，非甲基化与星形细胞瘤的总生存期不良相关。高 CD47、TIGIT 和 CD47/TIGIT 水平与 ADG 和 GBM 的生存显著降低相关。GBM、非甲基化和高 CD47 表达是 ADG 总生存期的独立预后因素。

讨论

综上所述，这些结果表明，非甲基化和 CD47、TIGIT 水平升高与 ADG 的不良预后相关。高 CD47 和 TIGIT 表达的患者可能受益于抗 CD47 和 TIGIT 免疫治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb26/10884119/179730c2bd0e/fimmu-15-1323307-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb26/10884119/87c725df51dc/fimmu-15-1323307-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb26/10884119/aecb6b8ccc89/fimmu-15-1323307-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb26/10884119/523b60b34640/fimmu-15-1323307-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb26/10884119/4685a75383a7/fimmu-15-1323307-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb26/10884119/179730c2bd0e/fimmu-15-1323307-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb26/10884119/87c725df51dc/fimmu-15-1323307-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb26/10884119/aecb6b8ccc89/fimmu-15-1323307-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb26/10884119/523b60b34640/fimmu-15-1323307-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb26/10884119/4685a75383a7/fimmu-15-1323307-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb26/10884119/179730c2bd0e/fimmu-15-1323307-g005.jpg

相似文献

1
MGMT unmethylation and high levels of CD47 and TIGIT indicate a poor prognosis in adult diffuse gliomas.MGMT 未甲基化以及高水平的 CD47 和 TIGIT 表明成人弥漫性神经胶质瘤预后不良。
Front Immunol. 2024 Feb 9;15:1323307. doi: 10.3389/fimmu.2024.1323307. eCollection 2024.
2
Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation.通过对 2016 年 WHO 弥漫性胶质瘤分类进行以下四项指标的细化：EGFR 扩增、TERT 突变、PTEN 缺失和 MGMT 甲基化，获得的临床见解。
BMC Cancer. 2019 Oct 17;19(1):968. doi: 10.1186/s12885-019-6177-0.
3
Prognostic Relevance of Tumor Purity and Interaction with MGMT Methylation in Glioblastoma.胶质母细胞瘤中肿瘤纯度的预后相关性及其与MGMT甲基化的相互作用
Mol Cancer Res. 2017 May;15(5):532-540. doi: 10.1158/1541-7786.MCR-16-0322. Epub 2017 Feb 1.
4
A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas.TERT 启动子突变与 MGMT 甲基化状态相结合可预测新诊断的胶质母细胞瘤中有临床意义的亚组。
Acta Neuropathol Commun. 2016 Aug 8;4(1):79. doi: 10.1186/s40478-016-0351-2.
5
Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas.端粒酶逆转录酶（TERT）启动子突变对弥漫性胶质瘤中异柠檬酸脱氢酶（IDH）突变和O6-甲基鸟嘌呤-DNA甲基转移酶（MGMT）启动子甲基化的临床意义
Pathol Res Pract. 2018 Jun;214(6):881-888. doi: 10.1016/j.prp.2018.04.002. Epub 2018 Apr 5.
6
Clinicopathological associations and prognostic values of IDH1 gene mutation, MGMT gene promoter methylation, and PD-L1 expressions in high-grade glioma treated with standard treatment.IDH1基因突变、MGMT基因启动子甲基化及PD-L1表达在接受标准治疗的高级别胶质瘤中的临床病理相关性及预后价值
Pan Afr Med J. 2020 Aug 20;36:309. doi: 10.11604/pamj.2020.36.309.24831. eCollection 2020.
7
The frequency and prognostic effect of TERT promoter mutation in diffuse gliomas.弥漫性胶质瘤中 TERT 启动子突变的频率及预后影响。
Acta Neuropathol Commun. 2017 Aug 29;5(1):62. doi: 10.1186/s40478-017-0465-1.
8
The global DNA methylation surrogate LINE-1 methylation is correlated with MGMT promoter methylation and is a better prognostic factor for glioma.全球 DNA 甲基化替代物 LINE-1 甲基化与 MGMT 启动子甲基化相关，是胶质母细胞瘤更好的预后因素。
PLoS One. 2011;6(8):e23332. doi: 10.1371/journal.pone.0023332. Epub 2011 Aug 4.
9
IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy.异柠檬酸脱氢酶（IDH）突变和O6-甲基鸟嘌呤-DNA甲基转移酶（MGMT）启动子甲基化与接受同步和辅助替莫唑胺化疗放疗的多形性胶质母细胞瘤患者的假性进展及预后改善相关。
Clin Neurol Neurosurg. 2016 Dec;151:31-36. doi: 10.1016/j.clineuro.2016.10.004. Epub 2016 Oct 12.
10
Extent and prognostic value of MGMT promotor methylation in glioma WHO grade II.胶质母细胞瘤二级中 MGMT 启动子甲基化的程度和预后价值。
Sci Rep. 2020 Nov 12;10(1):19758. doi: 10.1038/s41598-020-76312-x.

引用本文的文献

1
Immune checkpoints in immune response to glioma: two sides of the same coin.胶质瘤免疫反应中的免疫检查点：硬币的两面
Front Immunol. 2025 Aug 15;16:1639521. doi: 10.3389/fimmu.2025.1639521. eCollection 2025.

本文引用的文献

1
Tumor-selective Blockade of CD47 Signaling with CD47 Antibody for Enhanced Anti-tumor Activity in Malignant Meningioma.肿瘤选择性阻断 CD47 信号通路的 CD47 抗体增强恶性脑膜瘤的抗肿瘤活性。
Curr Neuropharmacol. 2023;21(10):2159-2173. doi: 10.2174/1570159X21666230511123157.
2
Molecular landscape of IDH-wild type, pTERT-wild type adult glioblastomas.IDH 野生型、pTERT 野生型成人弥漫性脑胶质瘤的分子特征。
Brain Pathol. 2022 Nov;32(6):e13107. doi: 10.1111/bpa.13107. Epub 2022 Jul 11.
3
Targeting PD-L1 and TIGIT could restore intratumoral CD8 T cell function in human colorectal cancer.
靶向 PD-L1 和 TIGIT 可恢复人类结直肠癌肿瘤内 CD8 T 细胞功能。
Cancer Immunol Immunother. 2022 Oct;71(10):2549-2563. doi: 10.1007/s00262-022-03182-9. Epub 2022 Mar 16.
4
IDH1/2 Mutations in Patients With Diffuse Gliomas: A Single Centre Retrospective Massively Parallel Sequencing Analysis.IDH1/2 突变在弥漫性神经胶质瘤患者中的分析：一项单中心回顾性大规模平行测序分析。
Appl Immunohistochem Mol Morphol. 2022 Mar 1;30(3):178-183. doi: 10.1097/PAI.0000000000000997.
5
Cancer statistics in China and United States, 2022: profiles, trends, and determinants.中国和美国 2022 年癌症统计数据：概况、趋势和决定因素。
Chin Med J (Engl). 2022 Feb 9;135(5):584-590. doi: 10.1097/CM9.0000000000002108.
6
Clinical strategies to manage adult glioblastoma patients without MGMT hypermethylation.治疗无MGMT基因高甲基化的成人间变性胶质瘤患者的临床策略。
J Cancer. 2022 Jan 1;13(1):354-363. doi: 10.7150/jca.63595. eCollection 2022.
7
Prognostic Impact of the Combination of Methylation and Promoter Mutation in Glioblastoma.胶质母细胞瘤中甲基化与启动子突变联合的预后影响
J Neurosci Rural Pract. 2021 Sep 28;12(4):694-703. doi: 10.1055/s-0041-1735821. eCollection 2021 Oct.
8
Targeting CD47 for cancer immunotherapy.针对 CD47 的癌症免疫疗法。
J Hematol Oncol. 2021 Oct 30;14(1):180. doi: 10.1186/s13045-021-01197-w.
9
The 2021 WHO Classification of Tumors of the Central Nervous System: a summary.2021 年世卫组织中枢神经系统肿瘤分类：概述。
Neuro Oncol. 2021 Aug 2;23(8):1231-1251. doi: 10.1093/neuonc/noab106.
10
Exosomal CD47 Plays an Essential Role in Immune Evasion in Ovarian Cancer.外泌体 CD47 在卵巢癌免疫逃逸中发挥重要作用。
Mol Cancer Res. 2021 Sep;19(9):1583-1595. doi: 10.1158/1541-7786.MCR-20-0956. Epub 2021 May 20.